Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Daklinza (daclatasvir) for the Treatment of Chronic Hepatitis C Genotype 3 Infection

Drug Name

Daklinza (daclatasvir)

Company / Licensee

Bristol-Myers Squibb

Current Indication

Chronic hepatitis C genotype 3 infection

Therapy Class

NS5A replication complex inhibitor

Market Sector

Anti-infectives

Development Status

Approved in the US, Europe, Japan and other countries in Asia-Pacific and Middle East
Expand

Go Top